3DMedcare

3DMedcare, founded in 2010, is an industry leader in the Biopharma, Biotechnology, Health Care, and Pharmaceutical sectors. This pioneering company originated in Shanghai and has since grown into a significant player in the precision medical diagnostics field, with over a thousand employees spread across China, the United States, and Singapore.

With a motto of providing precision diagnosis solutions to any patient, anytime, anywhere, 3DMedcare has developed a comprehensive diagnostic research platform. It integrates oncology, bioinformatics, electrical engineering, materials science, and big data analytics. The company's notable offerings include an NGS library prep automation system and a proprietary exosome biomarker detection platform for early cancer diagnosis, significantly contributing to the field.

3DMedcare last secured a Series D investment on 01 November 2020, supported by investors such as Innovitalize Capital, China Minsheng Investment Group, Fang Fund Partners, Tasly Pharmaceutical, and CTS Capital. This funding illustrates strong confidence from key investors and underpins the company's strategic ambitions in the global health care landscape.